Navigation Links
National Pharmaceutical Council Survey Shows Health Care Stakeholders Continue to Show Optimism About the Future Role of Comparative Effectiveness Research
Date:3/19/2013

WASHINGTON, March 19, 2013 /PRNewswire-USNewswire/ -- As the implementation of the Affordable Care Act (ACA) picks up speed, a new survey shows that health care stakeholders have growing expectations for the use of comparative effectiveness research (CER) as a tool for improving health care decision-making. The survey, the third in an annual series conducted by the National Pharmaceutical Council, also indicates that stakeholders are looking increasingly to the Patient-Centered Outcomes Research Institute (PCORI) as a leader in the CER effort.

"The potential for CER to re-shape the health care landscape is real, but the survey indicates that the actual impact is still on the horizon," said Dan Leonard , president of NPC. "Many health care stakeholders are not seeing an immediate impact from CER, but they do expect CER to have a larger impact on decision-making during the next five years."

During the next year, there is tempered optimism about CER, with 31 percent of respondents saying that CER will have a "moderate improvement" on health-care decision making over the next 12 months, which is a seven percentage point increase from 2012. It's during the next few years in which the full impact of CER is expected. Respondents felt much more confident about the impact of CER on health care decision-making over the next three to five years, with a "moderate improvement" indicated by 51 percent in the next three years, and 31 percent in the next five years. A "substantial improvement" was indicated by 24 percent over the next three years and 55 percent over the next five years.

Survey respondents also were asked which organizations they viewed as playing leading roles in CER. PCORI is viewed as leading on establishing research priorities (73 percent), closely followed by the National Institutes of Health (NIH) and the Agency for Healthcare Res
'/>"/>

SOURCE National Pharmaceutical Council
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
2. Austen BioInnovation Institute in Akron Attracts Nationally Known Speakers For Conference on Value-driven Engineering, April 23-24
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
5. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
6. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
7. Fuse Science Partners With GNC To Open National Distribution Of EnerJel™
8. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
9. Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering
10. WAISMANN METHOD® Director Encourages Public to Participate in National Take-Back Day
11. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015 Steven Rash , the CEO ... its operating subsidiary American Seed & Oil Company, presented ... investors yesterday in New York City.  Mr. Rash,s presentation ... American Seed & Oil Company has recently announced the ... Hemp Seed Foods , the EpiVape , and ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/256szd/corporate ) has announced ... in 2014 - a Perspective of Mental Health Patient ... For the first time, in 2014, the ... the pharmaceutical industry held by patient groups with an ... organisations representing all therapy areas. - Findings ...
(Date:4/16/2015)... April 16, 2015 Mindray Medical International ... and marketer of medical devices worldwide, announced today ... Exchange Commission an Annual Report on Form 20-F that ... 31, 2014. An electronic version of Mindray,s Annual ... investor relations website at  http://ir.mindray.com  or  http://www.sec.gov . ...
Breaking Medicine Technology:American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2
... May 22 Shire plc (LSE: SHP, Nasdaq: ... results of a study showing that coadministration of the ADHD ... (PPI) Prilosec OTC(R) 40 mg (20 mg X 2), did ... concentration of d -amphetamine to be reached in the ...
... Calif., May 21 Telik, Inc. (Nasdaq: TELK ... study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal ... annual meeting of the American Society of Clinical Oncology (ASCO) ... in Orlando, FL.Details of the presentation are as follows:, ...
Cached Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8
(Date:4/17/2015)... 17, 2015 Most dental patients are ... units are made overseas by foreign dental laboratories, according ... remain unregulated in more than 40 states by their ... Association of Dental Laboratories has created the ... among patients about the consequences that could be associated ...
(Date:4/17/2015)... Baptist Health and The University of Texas MD ... to transform oncology care in northeast Florida and southeast ... a joint cancer program to enhance patient access to ... Anderson Cancer Center is anticipated to open in the ... coordinated, multidisciplinary cancer care for adults in the region. ...
(Date:4/17/2015)... April 17, 2015 Scientists from ... multicenter team of U.S. and Venezuelan researchers, have ... in humans among an isolated tribe of Yanomami ... Bacterial diversity in the Yanomami, previously unexposed to ... nearly double that of people living in industrialized ...
(Date:4/17/2015)... Connie Casad, M.D., a well-known and ... with 30 years of practice experience in Dallas, Texas, ... of service for her patients with the availability of ... wellness books with a brief synopsis on each for ... interest in providing this service, Dr. Casad said, “Furnishing ...
(Date:4/17/2015)... Compare-autoinsurance.org has released a new blog post ... insurance quotes . , The online environment can ... cars. Drivers should always compare multiple car insurance policies ... is a competitive one, which means that customers can ... It is now possible to compare online car insurance ...
Breaking Medicine News(10 mins):Health News:National Association Urges Transparency in Dental Industry 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3Health News:Connie Casad, M.D. Provides Patients Recommended List of Wellness Books on Website 2Health News:The Best Auto Insurance Quotes Are Available Online! 2
... entirely online, announces participation of Dr. Larry Kaskel, Founder and Medical ... "Improved Patient Outcomes and Enhanced Revenue with Therapeutic Lifestyle Changes." ... ... CardioCareLive , the first of its kind online medical conference ...
... Economic Climate and Exceptional Events, - Operating Profitability Has Resisted Well, - Continued Reduction in Net Debt, ... 2007, Net sales ... 19.3 ... 11.5% 14.5%, Current operating income* ...
... NEW YORK, Feb. 18 The Michael J. ... million total to six teams working to develop ... visualize the clumping of the alpha-synuclein protein in ... accelerate research into the cause, progression and treatment ...
... The fight against bone disorders that affect ... from an ultrasound device being developed by space ... early prediction of bone disorders such as osteoporosis ... Biomedical Research Institute (NSBRI) scientists are developing ...
... Inc. (NYSE: WLP ) announced today that ... Attorney General regarding the manner in which out-of-network reimbursement ... the Agreement with the Attorney General, WellPoint has agreed ... it uses in determining out-of-network reimbursement for certain products ...
... Researchers at Rhode Island Hospital have completed a ... measures during a possible flu pandemic. Their study focused ... individuals showing no symptoms (asymptomatic) or from individuals who ... The researchers call on the scientific community to better ...
Cached Medicine News:Health News:Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy 2Health News:Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy 3Health News:PCAS: 2008 Results 2Health News:PCAS: 2008 Results 3Health News:Michael J. Fox Foundation Awards $1.9 Million for Development of Non-Invasive Neuroimaging Techniques in Living Brain 2Health News:Michael J. Fox Foundation Awards $1.9 Million for Development of Non-Invasive Neuroimaging Techniques in Living Brain 3Health News:SCAN: Delivering Bone Disorder Diagnosis, Fracture Healing 2Health News:SCAN: Delivering Bone Disorder Diagnosis, Fracture Healing 3Health News:WellPoint Joins New York Attorney General in Creation of New Independent Database for Out-of-Network Reimbursement 2Health News:Study calls for increased research in flu transmission to prepare for pandemic flu outbreak 2
... catheter or instrument introduction. The dual ... peeled away and removed. The maximum ... to be introduced should be measured ... sheath. Supplied sterile in peel-open packages. ...
... Used percutaneously to direct a ... wire guide to a specific ... has an inner stainless steel ... to the catheter shaft. Supplied ...
Used when establishing a percutaneous tract for nephrostomy drainage. The guide has a stiff shaft and a gradual transition to a very flexible distal tip. Supplied sterile in peel-open packages. Inten...
Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: